Authors
Latest:
Three Steps to Revitalizing the Life Sciences Industry with AI-Enabled TechnologiesMeeting demands of the new marketplace.
Latest:
COVID-19: Therapeutics Under InvestigationJanita Good looks at some of the therapeutics currently under investigation and the issues they have highlighted in the context of a pandemic.
Latest:
The Importance of Responsible and Transparent Communications in Pharma MarketingPharma marketing strategies that are both socially and ethically responsible can build long term success for the life sciences industry.
Latest:
Payers Believe Lowering Drug Prices While Improving Patient Access Is Possible—but There’s a CatchValue-based price for access (VBPA) may increase access of specialty drugs for patients.
Latest:
Are You Ready for the Telemedicine Revolution?A new patient journey is emerging. Gilda Sala, Trista Bridges, and Rune Soelvsteen offer easy steps to future-proof your company’s approach.
Latest:
Reducing Prescription Drug Costs for Seniors: The ABCs of ASP for Part DOutlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.
Latest:
Gross-to-Net is not just a process but a way for business growthDefining what Gross-to-Net mean and why it is important to Life Sciences companies; Identify who in the company benefits in utilizing information from GTN; Get insights to successfully define and manage GTN process
Latest:
In life sciences, the metaverse opportunity knocksHere are three mindsets for pharma companies to adopt now to reap the rewards of early action in the metaverse.
Latest:
The Three Core Ingredients of Lasting Patient EngagementBiopharma marketers use experience to grow brands into fixtures in patient discourse
Latest:
Challenges of Patient Engagement in Atopic DermatitisHannah Brown & Elizabeth Baynton explore the atopic dermatitis patient-doctor dynamic and identify opportunities to optimize patient outcomes.
Latest:
Prospective Measures to Combat Rising Drug Prices in GermanyThis article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.
Latest:
Remote Reliance: The Rise of Oncology Home CareWhile hurdles remain, home healthcare could deliver better patient-centered cancer care—providing improved outcomes, enhanced quality of life, and reduced strain on resources.
Latest:
Patient-Centricity in Biopharma: Selling Health Versus PillsDevesh Verma and Rebecca Lorenzo outline some the challenges and potential solutions to building a patient-centric culture
Latest:
IDMP in a COVID ContextLise Stevens explores what difference the ISO IDMP (Identification of Medicinal Products) data standards would have made in a COVID-19 context — in applications ranging from pharmacovigilance adverse event reporting and electronic prescribing to falsified medicines control.
Latest:
Why the Pandemic is Rewriting the Biopharma Rule BookChanges necessitated by COVID will drive unprecedented transformation of industry.
Latest:
China’s 2022 NRDL OutlookThe 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.
Latest:
A Brand Game-Changer? TikTok and Pharma MarketingIt’s time for pharma brands to recognize the potential of TikTok as a promotional platform and develop a strategy to not only stand out but make an impact.
Latest:
Climbing Health Care Costs Result in Elevated Employer VigilanceSoaring healthcare costs show little sign of slowing in 2024, with concerns growing about the affordability of medications and medical services.
Latest:
Are We Forgetting to Develop Vaccines for Diseases other than COVID?It's time to apply the same COVID-19 urgency to other devastating diseases, such as Alzheimer’s, write Andrea Pfeifer and William Mobley.
Latest:
3 ASCO Insights for Pharma CommunicatorsThe world’s largest cancer research meeting, the American Society of Clinical Oncology (ASCO) Annual Meeting, recently convened in person in Chicago after two years of being held virtually. Sara Baker and Kristine Austria Fan of Marina Maher Communications provide their takeaways from the meeting.
Latest:
Building Pharma and Lab Spaces in New Jersey 2021–Adapting to Changing NeedsNJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.
Latest:
Key Factors Attributing to a Successful Product LaunchWhat the c-suite should consider in today’s marketplace.
Latest:
Pharma’s Business Case for RWE: Tapping the Full Value From These InsightsHow drugmakers can better harness real-world evidence to drive their clinical and commercial objectives, while also providing greater clarity for healthcare providers and improved access to therapy for the patients they serve.
Latest:
A Culture of Quality: The Catalyst to Accelerate InnovationWhy enabling a shared culture of quality across an organization is key to maintaining pharma’s recent pace of innovation wins—while inspiring new levels of confidence.
Latest:
The Real Cost of State Drug Importation Programs? Patient SafetyImporting drugs from Canada may increase the risk of US citizens being exposed to unsafe medicines.
Latest:
Three Keys to Ireland’s Resilient Pharma IndustryRecent growth in pharma makes Ireland an ideal candidate for expansion opportunities.
Latest:
The Resilience of R&D: Pharma Posted Record Output in 2021Despite disruption from the COVID-19 pandemic still in full swing, life sciences innovation activity remained undeterred, a recent report from the IQVIA Institute for Human Data Science finds—outlining the key factors driving record-breaking growth.
